A recent meta‐analysis evaluated the diagnostic accuracy of PSMA PET‐targeted biopsy for detecting prostate cancer and the impact of the combination of PSMA PET and MRI49 including five prospective studies with a total of 497 patients who underwent PSMA PET. This evidence concerns the gene FOLH1 and Familial prostate cancer.